Peter Schultz

Peter Schultz has made innovative and pioneering contributions to the interface between chemistry and biology, notably the exploitation of molecular diversity in the synthesis of new medicines and materials, and the rational expansion of the genetic code.

Dr. Schultz has demonstrated that traditional chemical tools used together with modern cellular and molecular biology methods can enable chemists to manipulate cellular machinery in amazing new ways. For example, his work has allowed them to add new building blocks to the genetic code, removing a billion-year constraint on living organisms.

He has also harnessed molecular diversity to create new catalysts, medicines, and materials, first in reprogramming the immune system to make enzyme-like catalysts, and more recently developing and applying the use of large combinatorial libraries to find new materials and innovative drugs for aging, cancer, and infectious disease.

Coauthor of over 600 scientific publications, Dr. Schultz has trained over 300 coworkers and is currently President of Scripps Research and holds the Sam Skaggs Chair. He is a founder of nine companies that have pioneered the application of molecular diversity technologies to address mult